Polymorphisms in drug transporter and metabolism genes associated with resistance to imatinib in chronic myeloid leukemia: A systematic review and meta analysis

Cargando...
Miniatura

Fecha

2024

Autores

Arrieta Gómez, Ana Marcela
Díaz-Mendoza, María Antonia
Bello Lemus, Yesit
León-Mejía, Grethel
Ruiz Benitez, Martha Lucia

Título de la revista

ISSN de la revista

Título del volumen

Editor

Ediciones Universidad Simón Bolívar
MDPI
Facultad de Ciencias Básicas y Biomédicas

Resumen

The aim of this study was to establish the relationship between different polymorphisms in drug transporter and metabolizer genes and resistance to imatinib in chronic myeloid leukemia (CML). For this purpose, an exhaustive search was carried out in the Scopus, Web of Science, and PubMed databases using different combinations of keywords with different inclusion and exclusion criteria. The meta-analysis included nine studies that met the established criteria. The results of the study showed that the polymorphic variants AG and GG of CYP3A5*3 are associated with response to treatment, presenting a significantly lower risk with resistance to imatinib. Likewise, the variants T1236C and G2677T/A of the ABCB1 gene show a significant association with treatment efficacy. In addition, the genetic polymorphism 1236T, homozygous CC of the MDR1 gene, significantly influences the increased risk of cytogenetic relapse and the polymorphic variant 361G>A GA of the SLCO1A2 gene significantly affects the complete molecular response.

Descripción

Palabras clave

Citación

Gómez, A.M.A.; Díaz-Mendoza, M.A.; Lemus, Y.B.; León-Mejía, G.; Benitez, M.L.R. Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. Sci. Pharm. 2024, 92, 2. https://doi.org/10.3390/ scipharm92010002